Multiphasic 68Ga-PSMA PET/CT in the detection of early recurrence in prostate cancer patients with a PSA Level of Less Than 1 ng/mL: A prospective study of 135 patients
The Journal of Nuclear Medicine Oct 07, 2020
Beheshti M, Manafi-Farid R, Geinitz H, et al. - A prospective study was conducted to ascertain the effect of the multiphasic acquisition of 68Ga-PSMA PET/CT in the detection of recurrent prostate cancer in the early stage of biochemical recurrence with a prostate-specific antigen (PSA) level of less than 1 ng/mL. Researchers performed a prospective monocentric study on 135 prostate cancer patients with biochemical recurrence and a PSA level of less than 1 ng/mL. The results exhibited that in patients with a PSA level of 0.5–1.0 ng/mL, 68Ga-PSMA PET/CT showed promise for early detection of recurrent disease. Nevertheless, it displayed limited value in patients with a PSA level of less than 0.5 ng/mL. It was reported that multiphasic 68Ga-PSMA PET/CT led to a better determination of equivocal findings. Delayed acquisitions seem to have a greater impact on clarifying equivocal findings, although dynamic images may provide helpful information for the assessment of the prostate bed.
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries